Stocktoria
Compass Therapeutics, Inc. CMPX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-11-13
Compass Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | $0 | — | — |
| R&D expense | $56.0M | $42.3M | $38.1M | — | — |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Interest expense | — | — | — | $0 | $370,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| Operating cash flow | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Cash & equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
| Shareholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
Source: SEC EDGAR filings · CIK 0001738021 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.